Royalty Pharma reported 12% growth in Q1 royalty receipts, driven by Vertex, GSK, and Roche. Read why RPRX stock is a Buy.

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...

Right now, a fantastic tariff safe-haven stock, one that's climbed nearly 70% in three years, is offering investors a great ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals took a confidence hit as Leerink Partners downgraded the stock from “strong-buy” to a mere “hold,” ...

Entrada Therapeutics, Inc.’s TRDA share price has surged by 5.86%, which has investors questioning if this is right time to sell.

This was the stock's fourth consecutive day of losses.

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Royalty Receipts was $788 million in the first quarter of 2025, an increase of 12% compared to $705 million in the first quarter of 2024. The increase was primarily driven by strong growth from the ...

Shares of Vertex Pharmaceuticals Inc. VRTX shed 3.38% to $434.82 Wednesday, on what proved to be an all-around favorable ...